US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Brookfield Real Assets Income Fund Inc.

12.97

+0.01000.08%

Post-market: 12.92-0.0500-0.39%19:06 EDT

Volume:91.79K

Turnover:1.19M

Market Cap:716.65M

PE:-8.01

High:13.00

Open:13.00

Low:12.94

Close:12.96

Loading ...

Overview Company News Filings

Crude Oil Falls Over 1%; ISM Services PMI Tumbles In May

CPF Special, MediSave and Retirement Accounts’ interest rate remains at 4% for Q3 2025

Press Release: Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress

Press Release: Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV

Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination

Press Release: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis

Press Release: Brookfield Real Assets Income Fund Inc. Declares Q2 2025 Distribution Schedule

Press Release: Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress

Shanghai Henlius Biotech Gets Approval for Kidney Treatment Clinical Trial in China; Shares Rise 3%

MT Newswires Live

Press Release: Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights

CPF Special, MediSave and Retirement Accounts’ interest rate remains at 4% for Q2 2025

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights

RA International Announces Secondary Trading Facility Post-AIM Cancellation

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

Silver Housing Bonus scheme extended to more private property owners who downsize

RA International to Delist from AIM Following Shareholder Approval

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/RA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","market":"US","secType":"STK","nameCN":"Brookfield Real Assets Income Fund Inc.","latestPrice":12.97,"timestamp":1749240000000,"preClose":12.96,"halted":0,"volume":91792,"hourTrading":{"tag":"盘后","latestPrice":12.92,"preClose":12.97,"latestTime":"19:06 EDT","volume":1573,"amount":20333.9765,"timestamp":1749251172226},"delay":0,"floatShares":55254696,"shares":55254696,"eps":-1.61933,"marketStatus":"Market Closed","change":0.01,"latestTime":"06-06 16:00:00 EDT","open":13,"high":13,"low":12.94,"amount":1189555.843168,"amplitude":0.00463,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.61933,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1749456000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":12.96,"dividendRate":0.109483,"preHourTrading":{"tag":"盘前","latestPrice":13,"preClose":12.96,"latestTime":"08:57 EDT","volume":43,"amount":559.548981,"timestamp":1749214673645},"postHourTrading":{"tag":"盘后","latestPrice":12.92,"preClose":12.97,"latestTime":"19:06 EDT","volume":1573,"amount":20333.9765,"timestamp":1749251172226},"volumeRatio":0.6384652564271236},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","floatShares":55254696,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.6384652564271236,"shares":55254696,"dividePrice":1.42,"high":13,"amplitude":0.00463,"preClose":12.96,"low":12.94,"week52Low":11.87,"pbRate":"--","week52High":13.77,"institutionHeld":0,"latestPrice":12.97,"eps":-1.61933,"divideRate":0.109483,"volume":91792,"delay":0,"ttmEps":-1.61933,"open":13,"prevYearClose":13.32,"prevWeekClose":12.94,"prevMonthClose":12.94,"prevQuarterClose":13.16,"fiveDayClose":12.94,"twentyDayClose":12.8,"sixtyDayClose":13.26},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2541292098","title":"Crude Oil Falls Over 1%; ISM Services PMI Tumbles In May","url":"https://stock-news.laohu8.com/highlight/detail?id=2541292098","media":"Benzinga","labels":["economic"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2541292098?lang=en_us&edition=fundamental","pubTime":"2025-06-05 01:16","pubTimestamp":1749057361,"startTime":"0","endTime":"0","summary":" ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/market-summary/25/06/45777455/crude-oil-falls-over-1-ism-services-pmi-tumbles-in-may","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"economic","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANAB","BK4139","CLRB","BK4155",".IXIC","NQmain","TSYW.SI","TQQQ","MNQmain","BK4613","BK4579","RA","BK4108","ASAN","USJW.SI","BK4114","KWM","PSQ","BK4504","USAW.SI","DLTR","YEXT","SQQQ","BK4585","NVIW.SI","QID","QLD","LU0006061336.USD","BK4588","BK4023"],"gpt_icon":1},{"id":"2537960537","title":"CPF Special, MediSave and Retirement Accounts’ interest rate remains at 4% for Q3 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2537960537","media":"businesstimes","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537960537?lang=en_us&edition=fundamental","pubTime":"2025-05-22 03:55","pubTimestamp":1747857327,"startTime":"0","endTime":"0","summary":"Ordinary Account interest rate also remains at 2.5% per annum","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"bustime_highlight","url":"https://www.businesstimes.com.sg/companies-markets/cpf-special-medisave-and-retirement-accounts-interest-rate-remains-4-q3-2025","rn_cache_url":null,"customStyle":"","selectors":"body","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.businesstimes.com.sg/companies-markets/cpf-special-medisave-and-retirement-accounts-interest-rate-remains-4-q3-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bustime_highlight","symbols":["BK4523","LU0541502299.USD","LU1282648689.USD","LU2265009873.SGD","LU0390134368.USD","LU0287143357.SGD","LU1791710400.SGD","LU0197773673.USD","IE00B0JY6M65.USD","LU0348744763.USD","LU2279701549.SGD","BK4588","LU0708995666.HKD","IE00BYTNYM70.SGD","LU0630378429.USD","LU0197773160.USD","LU0231203729.USD","LU0630378692.HKD","SG9999014005.SGD","LU0431992006.USD","LU1267930656.SGD","LU2177674079.SGD","LU0541501648.USD","LU0918141887.USD","LU0348816934.USD","LU0528227936.USD","LU2226246903.HKD","SG9999014013.SGD","BK4017","RA","IE00B7N09G41.SGD","BK4535","LU1854104046.USD","LU1791710582.SGD","BK4211","HDB","CPF","LU2663582299.SGD","SG9999014021.USD","LU2008162690.USD","LU0868486357.SGD","LU1804176565.USD","LU0536402901.SGD","LU0797268264.HKD","LU0918141705.HKD","BK4566","LU0456842615.SGD","LU1508157978.USD","LU1805238398.USD"],"gpt_icon":0},{"id":"2534251872","title":"Press Release: Metsera Reports First Quarter 2025 Financial Results and Continued Portfolio Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2534251872","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2534251872?lang=en_us&edition=fundamental","pubTime":"2025-05-12 19:00","pubTimestamp":1747047600,"startTime":"0","endTime":"0","summary":"MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025. MET-233i, a monthly, ultra-long acting amylin analog, is in Phase 1 trials as a monotherapy and co-administered with MET-097i, with five-week monotherapy data expected in Q2 2025. MET-097 (,) an oral formulation of MET-097i, has been accelerated and alternate oral candidate MET-224 is on track, with four-week data for selected lead expected in late 2025. NEW YORK, May 12, 2025  -- Metsera, Inc. , a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today reported first quarter 2025 financial results and continued portfolio progress.\"The first quarter of 2025 was a period of focused execution and acceleration at Metsera,\" said Whit Bernard, Chief Executive Officer of Metsera. \"We remain on track to deliver on all of our committed clinical milestones fo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MTSR","LU2065732104.USD","RA","BK4097","BK4139","PRGS"],"gpt_icon":0},{"id":"2533184327","title":"Press Release: Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2533184327","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533184327?lang=en_us&edition=fundamental","pubTime":"2025-05-08 20:00","pubTimestamp":1746705600,"startTime":"0","endTime":"0","summary":"IND clearance and initiation of global basket trial exploring AlloNK + rituximab in refractory rheumatoid arthritis, Sjgren's disease, idiopathic inflammatory myopathies and systemic sclerosis. First trial to explore an allogeneic cell therapy in refractory rheumatoid arthritis and Sjgren's disease in the U.S.Initial safety, translational data, and lead indication selection to be presented by year-end 2025; initial clinical response data in the lead indication to be presented in 1H2026. Dr. Aslan continued, \"Our longer-term aggressive B-NHL data is maturing into a leading data set, in line with approved auto-CAR-T therapies, providing proof of concept of AlloNK's ability to deplete B-cells deeply and durably. We remain well capitalized to gene","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4077","SLE","ARTV","BK4022","R","RA","BK4232"],"gpt_icon":0},{"id":"2533689545","title":"Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2533689545","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533689545?lang=en_us&edition=fundamental","pubTime":"2025-05-06 04:15","pubTimestamp":1746476100,"startTime":"0","endTime":"0","summary":"Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis  trial; to present updated clinical and translational data in the first week of June. Initial Phase 2 data for rosnilimab in ulcerative colitis  on track for Q4 2025. Ongoing Phase 1a trials in healthy volunteers for ANB033, a CD122 antagonist, and ANB101, a BDCA2 modulator. Enrollment ongoing for global Phase 2 trial in moderate-to-severe UC. All patients in all three study arms treat-through to Week 24 and remain blinded to treatment arm. Placebo-treated patients who achieved clinical response on partial modified Mayo score  at Week 12 remain on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/anaptys-announces-first-quarter-2025-201500724.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TEP","BK4144","LU0053666078.USD","RA","BK4139","BK4590","BK4588","L","ANAB","BK4107","GPP","BK4585"],"gpt_icon":0},{"id":"2532846095","title":"Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV","url":"https://stock-news.laohu8.com/highlight/detail?id=2532846095","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532846095?lang=en_us&edition=fundamental","pubTime":"2025-05-02 19:30","pubTimestamp":1746185400,"startTime":"0","endTime":"0","summary":"VAMOS analysis highlights link between EVAF and reduced muscle quality. Case series reports success with combination tesamorelin/GLP-1 receptor agonist therapy. “We are proud to continue our exploration into the complexities of excess visceral abdominal fat in people with HIV,” said Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer of Theratechnologies. “As people with HIV live longer, analyses such as the data we are presenting at ACTHIV are critical to addressing this population’s evolving health needs. Our research adds to the growing understanding that body composition, most importantly EVAF, is a key factor in aging-related functional decline in HIV, and we are committed to investigating this complex relationship.”","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/theratechnologies-presents-novel-data-acthiv-113000123.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BMI","BK4157","THTX","RA"],"gpt_icon":0},{"id":"2532002808","title":"Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2532002808","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532002808?lang=en_us&edition=fundamental","pubTime":"2025-05-01 21:30","pubTimestamp":1746106200,"startTime":"0","endTime":"0","summary":"18 presentations across five cancer types include new insights on the potential of checkpoint inhibitors and bispecific antibodies. TARRYTOWN, N.Y., May 01, 2025  -- Regeneron Pharmaceuticals, Inc.  today announced new and updated data from its oncology and hematology portfolio will be shared at the 2025 American Society of Clinical Oncology  Annual Meeting, taking place from May 30 to June 3 in Chicago, IL. Eighteen presentations will share the latest insights from ongoing research of approved and investigational treatment regimens across a range of difficult-to-treat cancers including non-melanoma and melanoma skin cancer, lung cancer, lymphoma and multiple myeloma.The full list of Regeneron presentations at ASCO includes:","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regeneron-highlight-advances-asco-phase-133000246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0390134368.USD","SGXZ51526630.SGD","LU0823417737.USD","SGXZ31699556.SGD","LU2361044865.SGD","LU1791710582.SGD","LU1435385759.SGD","LU2028103732.USD","REGN","LU1691799644.USD","LU0528227936.USD","LU0128525929.USD","GB00B4QBRK32.GBP","BTZ","LU0256863902.USD","LU1429558221.USD","LU0316494557.USD","LU1267930573.SGD","LU1712237335.SGD","LU2360032135.SGD","LU0965508806.USD","LU0061474960.USD","LU1852331112.SGD","LU0154236417.USD","SG9999018857.SGD","LU0048584097.USD","LU1046421795.USD","LU0444971666.USD","BK4588","LU0417517546.SGD","LU2023250504.SGD","LU1267930730.SGD","LU0823434583.USD","FL","LU2089284900.SGD","LU2125154935.USD","LU2404859667.USD","LU0158827781.USD","RA","LU0353189680.USD","IE00B19Z8W00.USD","BCC","LU2023250843.SGD","SG9999014914.USD","LU0342679015.USD","LU0426412945.USD","LU1815333072.USD","LU0265550946.USD","LU0823434740.USD"],"gpt_icon":1},{"id":"2526384049","title":"Press Release: Artiva Biotherapeutics Appoints Subhashis Banerjee, M.D., as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526384049","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526384049?lang=en_us&edition=fundamental","pubTime":"2025-04-09 04:05","pubTimestamp":1744142700,"startTime":"0","endTime":"0","summary":"Dr. Banerjee's appointment culminates Artiva's efforts to build a seasoned development team with strong expertise in autoimmune diseases and cell therapy. Dr. Banerjee added, \"Artiva is leading the development of NK cell treatments for autoimmune disease, with the potential to offer a much-needed, long-term therapeutic option with an accessibility and safety profile that enables broad use in a community setting. The robust B-cell depletion seen with AlloNK through enhanced antibody-directed killing of cells in non-Hodgkin lymphoma bodes well for our opportunity to deeply deplete B-cells in patients with autoimmune diseases and to bring about meaningful clinical improvements and medication reductions. Artiva has built a very seasoned development team, and I am excited to lead the effort to further define the indications where AlloNK can be most impactful, and to help drive the program towards late-stage development.\"","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IIM","BK4139","BK4232","BMS","R","RA","SLE","BK4077","BK4022","ARTV"],"gpt_icon":0},{"id":"2525834416","title":"AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults with Giant Cell Arteritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2525834416","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525834416?lang=en_us&edition=fundamental","pubTime":"2025-04-08 14:00","pubTimestamp":1744092000,"startTime":"0","endTime":"0","summary":"RINVOQ is the first and only oral Janus kinase  inhibitor approved in the European Union  to treat adult patients with giant cell arteritis . The approval is supported by data from the pivotal Phase 3 SELECT-GCA trial which demonstrated that RINVOQ achieved the primary endpoint of sustained remission* and key secondary endpoints, including reduction in disease flares, lower cumulative steroid exposure and complete remission 1. This marks the eighth approved indication for RINVOQ in the EU2. NORTH CHICAGO, Ill., April 8, 2025 /PRNewswire/ -- AbbVie  today announced that the European Commission  granted marketing authorization to RINVOQ  for the treatment of giant cell arteritis  in adult patients. RINVOQ is the first and only oral JAK inhibitor approved in the EU, as well as Iceland, Liechtenstein and Norway, for the treatment of adult patients with GCA.GCAis an autoimmune disease that causes inflammation of the temporal and other cranial arteries, the aorta, and other large and medium ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/abbvie-announces-european-commission-approval-060000872.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbvie-announces-european-commission-approval-060000872.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999015986.USD","LU2237443978.SGD","IE0004445239.USD","LU0198837287.USD","BK4007","LU2023251221.USD","LU2087621335.USD","IE00B42XCP33.USD","BK4559","BK4156","ALT","ABBV","LU0211327993.USD","LU0320765646.SGD","LU1037948897.HKD","LU1093756168.USD","BK4139","LU2129689431.USD","LU2112291526.USD","LU2237443895.HKD","LU0965508806.USD","IE0009355771.USD","LU0861579265.USD","LU1878469433.USD","IE00BDGV0183.EUR","LU1162221912.USD","EC","LU2237443622.USD","LU0965509101.SGD","LU1061106388.HKD","RA","IE00BFTCPJ56.SGD","TAK","IE00B2B36J28.USD","LU1093756325.SGD","LU1003077747.HKD","LU1934455194.USD","LU0211328371.USD","LU1551013342.USD","CPK","LU0234570918.USD","LU1551013425.SGD","SG9999015978.USD","SG9999015945.SGD","LU0456855351.SGD","LU2237443465.HKD","LU1718418525.SGD","IE00BVYPNV92.GBP","IE00BJT1NW94.SGD"],"gpt_icon":0},{"id":"2523633325","title":"Press Release: Brookfield Real Assets Income Fund Inc. Declares Q2 2025 Distribution Schedule","url":"https://stock-news.laohu8.com/highlight/detail?id=2523633325","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523633325?lang=en_us&edition=fundamental","pubTime":"2025-03-29 04:34","pubTimestamp":1743194040,"startTime":"0","endTime":"0","summary":"NEW YORK, March 28, 2025  -- Brookfield Real Assets Income Fund Inc.   today announced that its Board of Directors  declared the Fund's monthly distributions for April, May and June 2025.April 2025   April 10, 2025   April 10, 2025   April 24, 2025          $0.1180. May 2025     May 8, 2025      May 8, 2025      May 22, 2025            $0.1180. June 2025    June 12, 2025    June 12, 2025    June 26, 2025           $0.1180. Investing involves risk; principal loss is possible. Past performance is not a guarantee of future results.Brookfield Real Assets Income Fund Inc. is distributed by Foreside Fund Services, LLC.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA"],"gpt_icon":0},{"id":"2522829878","title":"Press Release: Metsera Reports Fourth Quarter and Full Year 2024 Financial Results and Continued Portfolio Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2522829878","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522829878?lang=en_us&edition=fundamental","pubTime":"2025-03-26 19:00","pubTimestamp":1742986800,"startTime":"0","endTime":"0","summary":"MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025. Multiple data readouts in mid and late 2025 on track for MET-233i, an ultra-long acting amylin analog currently in Phase 1. Oral formulation optimization study on track to support initiation of clinical trials for MET-224 and MET097 , with MET-224 data expected in late 2025. Completed IPO with gross proceeds of approximately $316.2 million, extending runway into 2027. NEW YORK, March 26, 2025  -- Metsera, Inc. , a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases, today reported fourth quarter and full year 2024 financial results and provided an update on pipeline progress.With the completion of our recent IPO, we have substantial capital to continue this momentum, enabled by our highly experienced team and committed partners. We expect 2025 to be anot","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IPO","LU2065732104.USD","BK4097","PRGS","MTSR","RA"],"gpt_icon":0},{"id":"2522181554","title":"Shanghai Henlius Biotech Gets Approval for Kidney Treatment Clinical Trial in China; Shares Rise 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522181554","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522181554?lang=en_us&edition=fundamental","pubTime":"2025-03-26 15:21","pubTimestamp":1742973671,"startTime":"0","endTime":"0","summary":"Shanghai Henlius Biotech  said that China's National Medical Products Administration  approved an application for a Phase 2 clinical trial of HLX79 injection in combination with Hanlikang for the treatment of active glomerulonephritis, according to a filing made on Tuesday with the Hong Kong bourse.HLX79 is a sialidase fusion protein made by combining a human sialidase enzyme with a human monoclonal antibody.Hanlikang is approved in Mainland China for non-Hodgkin's lymphoma , chronic lymphocytic leukemia , and rheumatoid arthritis .The pharmaceutical company's shares were up 3% in recent trading.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RA","BK1161","02696"],"gpt_icon":0},{"id":"2522707632","title":"Press Release: Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2522707632","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522707632?lang=en_us&edition=fundamental","pubTime":"2025-03-25 04:05","pubTimestamp":1742846700,"startTime":"0","endTime":"0","summary":"Initial data for AlloNK from autoimmune program expected H1 2025. Updated clinical data from Phase 1/2 trial exploring AlloNK + rituximab in NHL showing continued durability of response to be presented at a medical conference in 2025. Strengthened key leadership with cell therapy and autoimmune expertise across organization. Robust balance sheet with cash, cash equivalents and investments of $185.4 million as of December 31, 2024, is expected to fund operations at least through end of 2026. SAN DIEGO, March 24, 2025  -- Artiva Biotherapeutics, Inc.  , a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced financial results for the full year ended December 31, 2024, and highlighted recent progress.Officer of Cue Biopharma, Inc., and previously held a 19-year tenure at","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4077","SLE","BK4232","BK4139","RA","ARTV","BK4022"],"gpt_icon":0},{"id":"2518878440","title":"CPF Special, MediSave and Retirement Accounts’ interest rate remains at 4% for Q2 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2518878440","media":"businesstimes","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518878440?lang=en_us&edition=fundamental","pubTime":"2025-03-12 03:07","pubTimestamp":1741720057,"startTime":"0","endTime":"0","summary":"Rates for the Ordinary Account and HDB housing loans are also unchanged","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"bustime_highlight","url":"https://www.businesstimes.com.sg/companies-markets/cpf-special-medisave-and-retirement-accounts-interest-rate-remains-4-q2-2025","rn_cache_url":null,"customStyle":"","selectors":"body","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.businesstimes.com.sg/companies-markets/cpf-special-medisave-and-retirement-accounts-interest-rate-remains-4-q2-2025","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bustime_highlight","symbols":["LU0348744763.USD","LU0797268264.HKD","HDB","LU1805238398.USD","LU0541501648.USD","LU0868486357.SGD","LU1791710582.SGD","LU1854104046.USD","LU0348814723.USD","LU2177674079.SGD","BK4566","LU0456842615.SGD","BK4588","LU0287143357.SGD","BK4017","RA","LU2279701549.SGD","LU0708995666.HKD","BK4585","LU0197773673.USD","LU0390134368.USD","LU0918141887.USD","BK4207","LU0197773160.USD","LU1282648689.USD","LU0918141705.HKD","LU2265009873.SGD","LU0231203729.USD","LU2226246903.HKD","LU1804176565.USD","BK4211","LU0630378692.HKD","LU0348816934.USD","LU1791710400.SGD","LU0630378429.USD","LU0541502299.USD","LU1105468828.SGD","LU0536402901.SGD","LU2008162690.USD","CPF","LU1267930656.SGD","BK4523","LU0197229882.USD","SG9999014005.SGD","LU0528227936.USD","BK4535","SG9999014013.SGD","SG9999014021.USD","LU0431992006.USD"],"gpt_icon":0},{"id":"2518482877","title":"Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2518482877","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518482877?lang=en_us&edition=fundamental","pubTime":"2025-03-11 20:00","pubTimestamp":1741694400,"startTime":"0","endTime":"0","summary":"Delivered record full-year total revenue and AVISE CTD average selling priceImproved full-year adjusted EBITDA loss and cash use by over 40%Commercialized new biomarkers to enhance clinical utility of AVISE CTD. CARLSBAD, Calif., March 11, 2025  -- Exagen Inc. ,a leading provider of autoimmune testing, today reported financial results for the fourth quarter and full year ended December 31, 2024, and recent business highlights.Achieved key commercial milestone with completion of 1,000,000th patient tested by AVISE CTD. Featured five abstracts at the 2024 American College of Rheumatology  annual meeting highlighting Exagen’s innovative research on novel T Cell biomarkers for Lupus and sero-negative autoantibodies for rheumatoid arthritis, in addition to a plenary presentation in collaboration with Johns Hopkins University, highlighting a urinary biomarker panel that holds the potential to guide precision management of Lupus Nephritis patients. Secured New York State Department of Health ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exagen-inc-reports-strong-fourth-120000907.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SLE","BK4110","BK4139","BK4077","RA","XGN","ACR"],"gpt_icon":0},{"id":"2518206289","title":"RA International Announces Secondary Trading Facility Post-AIM Cancellation","url":"https://stock-news.laohu8.com/highlight/detail?id=2518206289","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518206289?lang=en_us&edition=fundamental","pubTime":"2025-03-11 02:17","pubTimestamp":1741630640,"startTime":"0","endTime":"0","summary":"An update from RA International Group Plc ( ($GB:RAI) ) is now available. RA International Group PLC has announced the details of a secondary marke...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ra-international-announces-secondary-trading-facility-post-aim-cancellation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ra-international-announces-secondary-trading-facility-post-aim-cancellation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4212","BK4139","POST","RA","BK4557","AIM"],"gpt_icon":0},{"id":"2518423051","title":"Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study","url":"https://stock-news.laohu8.com/highlight/detail?id=2518423051","media":"PR Newswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518423051?lang=en_us&edition=fundamental","pubTime":"2025-03-09 02:00","pubTimestamp":1741456800,"startTime":"0","endTime":"0","summary":"Late-breaking results presented at AAD show 80% or more scalp hair coverage at Week 36 in 42.4% of adolescents receiving baricitinib 4 mg. Patients treated withbaricitinib 4 mg saw significant regrowth of eyebrows and eyelashes at Week 36 compared to placebo. Positive data underscore Lilly's continued expansion across dermatologic conditions, with treatments that can improve outcomes for patients with the greatest need","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/lillys-baricitinib-delivered-high-rates-180000752.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/lillys-baricitinib-delivered-high-rates-180000752.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MACE","LU0289739699.SGD","LU1868836914.USD","ALT","BK4533","LU1061106388.HKD","LU2023250504.SGD","LU1267930730.SGD","LU0320765059.SGD","LU2361045086.USD","LU2468319806.SGD","LU0823416689.USD","LU0097036916.USD","LU0471298777.SGD","LLY","LU0672654240.SGD","SG9999017495.SGD","BK4532","LU2361044949.HKD","LU2237443895.HKD","LU0471298694.HKD","LU1720051017.SGD","IE00BK4W5M84.HKD","IE0002141913.USD","LU1093756325.SGD","LU2237443622.USD","SG9999014914.USD","ALC","LU1023059063.AUD","LU1069344957.HKD","LU2602419157.SGD","BNTX","LU0354030511.USD","INCY","RA","IE00B4R5TH58.HKD","LU1548497426.USD","SG9999015945.SGD","LU0203201768.USD","LU2461242641.AUD","LU0198837287.USD","LU2237443978.SGD","BK4157","SG9999014880.SGD","IE00BFTCPJ56.SGD","LU1878469433.USD","LU2491049909.HKD","SGXZ81514606.USD","BK4548","LU2106854487.HKD"],"gpt_icon":1},{"id":"2517959757","title":"Silver Housing Bonus scheme extended to more private property owners who downsize","url":"https://stock-news.laohu8.com/highlight/detail?id=2517959757","media":"businesstimes","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517959757?lang=en_us&edition=fundamental","pubTime":"2025-03-05 03:58","pubTimestamp":1741118303,"startTime":"0","endTime":"0","summary":"Scheme incentivises seniors to sell their homes to move into a smaller HDB flat and boost their retirement income ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"bustime_highlight","url":"https://www.businesstimes.com.sg/property/silver-housing-bonus-scheme-extended-more-private-property-owners-who-downsize","rn_cache_url":null,"customStyle":"","selectors":"body","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.businesstimes.com.sg/property/silver-housing-bonus-scheme-extended-more-private-property-owners-who-downsize","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bustime_highlight","symbols":["5OC.SI","RA","BK6520","BK6045"],"gpt_icon":0},{"id":"2516037127","title":"RA International to Delist from AIM Following Shareholder Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2516037127","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516037127?lang=en_us&edition=fundamental","pubTime":"2025-03-01 00:47","pubTimestamp":1740761269,"startTime":"0","endTime":"0","summary":"RA International Group Plc ( ($GB:RAI) ) just unveiled an update. RA International Group PLC announced the approval of a resolution to cancel the a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ra-international-to-delist-from-aim-following-shareholder-approval?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ra-international-to-delist-from-aim-following-shareholder-approval?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RA","AIM","BK4557","BK4139"],"gpt_icon":0},{"id":"2514313647","title":"AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults with Giant Cell Arteritis","url":"https://stock-news.laohu8.com/highlight/detail?id=2514313647","media":"PR Newswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514313647?lang=en_us&edition=fundamental","pubTime":"2025-02-28 15:00","pubTimestamp":1740726000,"startTime":"0","endTime":"0","summary":"The positive opinion is based on results from the pivotal Phase 3SELECT-GCA trial that evaluated the efficacy and safety ofupadacitinib in adults with giant cell arteritis 1. The primary endpoint of sustained remission* and key secondary endpoints, including reduction in disease flares, lower cumulative steroid exposure, and complete remission, were met1. GCAis an autoimmune disease that causes inflammation of the large and medium cranial arteries, resulting in potentially debilitating symptoms2. NORTH CHICAGO, Ill., Feb. 28, 2025 /PRNewswire/ -- AbbVie  today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use  adopted a positive opinion recommending the approval of upadacitinib for the treatment of adult patients with GCA. The final European Commission decision is expected in the first half of 2025. If approved, upadacitinib would be the first and only oral advanced therapy for adults living with GCA.*Sustained remission is defined as having ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/abbvie-receives-positive-chmp-opinion-070000671.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abbvie-receives-positive-chmp-opinion-070000671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2468319806.SGD","RA","LU0661504455.SGD","LU0795875086.SGD","LU1878469433.USD","LU2347655156.SGD","LU0256863902.USD","LU2237443895.HKD","LU1003077747.HKD","LU0882574055.USD","LU1551013342.USD","LU0861579265.USD","LU0949170772.SGD","BK4588","BK4566","CHMP","LU1037948541.HKD","CPK","LU1934455863.HKD","BK4139","LU0943347566.SGD","LU0417517546.SGD","BK4534","LU0553294199.USD","LU0820561818.USD","SG9999003800.SGD","BK4581","BK4599","LU0198837287.USD","BK4007","LU1989771016.USD","BK4197","LU1585245621.USD","LU0689472784.USD","LU0545039389.USD","LU1061106388.HKD","LU0114720955.EUR","LU0122379950.USD","LU1718418525.SGD","LU2237443978.SGD","TAK","IE00BJJMRZ35.SGD","LU1244550221.USD","LU2237443382.USD","SG9999001440.SGD","ALT","LU1267930573.SGD","LU0708994859.HKD","ABBV"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":40,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RA\",params:#limit:5,,,undefined,":[{"date":"2025-06-12","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-12","defaultRemindTime":1749735000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-26","payableDate":"2025-06-12","currency":"USD","dateTimestamp":1749700800000,"payDate":"2025-06-26"},{"date":"2025-05-08","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-08","defaultRemindTime":1746711000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-22","payableDate":"2025-05-08","currency":"USD","dateTimestamp":1746676800000,"payDate":"2025-05-22"},{"date":"2025-04-10","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-10","defaultRemindTime":1744291800000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-24","payableDate":"2025-04-10","currency":"USD","dateTimestamp":1744257600000,"payDate":"2025-04-24"},{"date":"2025-03-13","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-13","defaultRemindTime":1741872600000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-27","payableDate":"2025-03-13","currency":"USD","dateTimestamp":1741838400000,"payDate":"2025-03-27"},{"date":"2025-02-06","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-06","defaultRemindTime":1738852200000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-20","payableDate":"2025-02-06","currency":"USD","dateTimestamp":1738818000000,"payDate":"2025-02-20"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RA\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-13","recordDate":"2016-12-15","paymentDate":"2016-12-22","value":0.199,"currency":"USD"},{"executeDate":"2017-03-14","recordDate":"2017-03-16","paymentDate":"2017-03-23","value":0.199,"currency":"USD"},{"executeDate":"2017-04-18","recordDate":"2017-04-20","paymentDate":"2017-04-27","value":0.199,"currency":"USD"},{"executeDate":"2017-05-16","recordDate":"2017-05-18","paymentDate":"2017-05-25","value":0.199,"currency":"USD"},{"executeDate":"2017-06-13","recordDate":"2017-06-15","paymentDate":"2017-06-22","value":0.199,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RA\",market:\"US\",delay:false,,,undefined,":{}}}